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Abstract: The detailed kinetic model of Prostaglandin H Synthase-1 (PGHS-1) was 
applied to in silico screening of dose-dependencies for the different types of nonsteroidal 
anti-inflammatory drugs (NSAIDs), such as: reversible/irreversible, nonselective/selective 
to PGHS-1/PGHS-2 and time dependent/independent inhibitors (aspirin, ibuprofen, 
celecoxib, etc.) The computational screening has shown a significant variability in the 
IC50s of the same drug, depending on different in vitro and in vivo experimental conditions. 
To study this high heterogeneity in the inhibitory effects of NSAIDs, we have developed 
an in silico approach to evaluate NSAID action on targets under different PGHS-1 
microenvironmental conditions, such as arachidonic acid, reducing cofactor, and peroxide 
concentrations. The designed technique permits translating the drug IC50, obtained in one 
experimental setting to another, and predicts in vivo inhibitory effects based on the relevant 
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in vitro data. For the aspirin case, we elucidated the mechanism underlying the 
enhancement and reduction (aspirin resistance) of its efficacy, depending on PGHS-1 
microenvironment in in vitro/in vivo experimental settings. We also present the results of 
the in silico screening of the combined action of sets of two NSAIDs (aspirin with 
ibuprofen, aspirin with celecoxib), and study the mechanism of the experimentally 
observed effect of the suppression of aspirin-mediated PGHS-1 inhibition by selective and 
nonselective NSAIDs. Furthermore, we discuss the applications of the obtained results to 
the problems of standardization of NSAID test assay, dependence of the NSAID efficacy 
on cellular environment of PGHS-1, drug resistance, and NSAID combination therapy. 
Keywords: kinetic modeling; COX-1,2; NSAID; aspirin resistance; NSAID combination 
 
1. Introduction  
The key pharmacological targets of NSAIDs are two isoforms of Prostaglandin H Synthase (PGHS) 
–PGHS-1 and PGHS-2 (also referred to as cyclooxygenase-1,2, COX-1,2) [1,2]. PGHS is a complex 
bifunctional, membrane-bound enzyme, which has two catalytic sites: a cyclooxygenase site  
(COX-site), in which the substrate, arachidonic acid, AA is oxygenized to the intermediate product, 
prostaglandin G2 (PGG2), and a peroxidase site (POX-site), in which PGG2 is reduced to the final 
product, prostaglandin H2 (PGH2) [2].  
Extensive studies of the enzyme have shown that PGHS catalysis is a complex phenomenon, 
involving the formation of multiple enzyme intermediates, redox transformation of key catalytic 
components by intraprotein electron transport, cooperative interaction of POX and COX activities, 
self-inactivation, and activation threshold of the enzyme. Despite significant progress in the study of 
PGHS over more than 30 years, many features of the enzyme catalysis are still to be clarified [3].  
It is suggested that the complex properties of the enzyme determine strict regulation of the synthesis 
of prostaglandin H2, a precursor of signaling prostanoid molecules such as prostacyclin,  
thromboxane, etc. [3,4]. Furthermore, it has been shown that the specific properties of PGHS manifest 
themselves significantly in the inhibitory effects of NSAIDs [1,5,6]. In particular, the structure of the 
catalytic COX-site, comprised of a hydrophobic channel for AA binding, defines several classes of 
NSAIDs that differ from one another in the mechanisms of binding with this channel: irreversible 
(aspirin), reversible (naproxen, diclofenac), time-dependent (indomethacin, celecoxib),  
time-independent (ibuprofen, naproxen), and selective to COX-1 or COX-2 NSAIDs [7–10]. 
The other indication of the complex dynamics of the interaction of PGHS with NSAIDs was 
observed in the experimental screening of NSAID dose-dependencies, drug IC50s, and  
selectivity [7,9,11–17]. These experimental data showed that drug effects depend dramatically on the 
experimental assays and microenvironment of PGHS-1. The experimental study of NSAID inhibition 
effects is commonly performed with the use of different assays, among them: purified  
PGHS-1,2 [7,11–13], intact cells (platelet, endothelial cells and others) [13–16], and human whole 
blood assay (WBA) [9,17]. The key properties of NSAIDs, such as dose-dependencies, IC50s, their 
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basic types, and mechanism of action were mainly characterised in in vitro experimental screenings 
with the use of cell-free preparations of PGHS-1,2 [7,11,12].  
The experimental results showed that IC50s and selectivity values obtained for the same NSAID in 
different experimental settings, may differ from each other by up to two orders of magnitude [10,14]. 
Moreover, two drugs may produce equivalent effects in one assay and show different effects under 
other conditions [17]. As a result of experimental studies, it was suggested that the key factor causing 
the variation in NSAID effects, is the difference between in vitro experimental conditions and the 
intracellular microenvironments in various cells [17]. The observed variation of drug IC50 complicates 
the comparison of the different drug efficacies. This effect also makes difficult to translate the results, 
obtained in in vitro, to in vivo conditions [10,14]. Furthermore, discrepancy and uncertainty in IC50 
values and selectivity of some NSAIDs, lead to uncertainty in the prediction of the side effects of the 
drugs, which are determined by their selectivity to PGHS-1/PGHS-2 [18].  
On one hand this problem points to the need for a standardization of the drug testing assays which 
would permit the comparison of different compounds [10,17]. On the other hand, the observed 
discrepancy of the IC50s indicates the large sensitivity of NSAIDs to the PGHS environment and cell 
types. The variation in the sensitivity of NSAIDs observed in in vivo assays is likely to exhibit itself on 
the organism level, in the form of variability of the response of different individuals to the same drug. 
For example, clinical studies show the heterogeneity in the suppression of platelet PGHS-1 activity by 
aspirin, and low response to aspirin in patients with coronary heart disease versus a healthy  
cohort [19,20]. Low aspirin responsiveness or aspirin resistance [21] is assumed to be caused by 
hyperactive platelets due to the local high concentration of AA at the site of vascular injury [22,23].  
Another clinical observation of different individuals’ response to NSAIDs relates to the variation in 
cardiovascular side effects, found among individuals taking PGHS-2 inhibitors. The reasons for aspirin 
resistance and an individual’s risk of cardiovascular complications remain an unanswered  
question [20,24,25]. 
To analyse the variation of NSAID effects, we have developed an in silico experimental method to 
screen the NSAID action in the different microenvironment of PGHS-1. The computational simulation 
method is based on the detailed kinetic model of drug target and NSAIDs interaction with PGHS-1. 
The developed technique allows studying what influence a drug target’s microenvironment can have 
on the resulting drug effects. 
In this work we demonstrate the abilities of the in silico screening method through its application to 
three NSAIDs: aspirin, ibuprofen, and celecoxib. These drugs represent three different classes of 
NSAIDs: aspirin is an irreversible, time-dependent traditional NSAID with preferential selectivity to 
PGHS-1 [13,16]; ibuprofen is a reversible, time-independent, PGHS-1 selective inhibitor, whereas 
celecoxib belongs to a new generation of PGHS-2 selective inhibitors with reversible time-independent 
binding to PGHS-1 and time-dependent binding to PGHS-2 [7]. Based on the calculations of the  
dose- dependencies for these drugs, we discuss the mechanisms of IC50 dependence on different 
PGHS-1 environmental conditions. 
We also applied the computational screening method to study the problem of the combined action 
of two NSAIDs on PGHS-1. Administration of combined NSAID therapy is recommended for patients 
who take low-dose aspirin to reduce the risk of recurrent myocardial infarction or a stroke, while using 
NSAIDs such as celecoxib, ibuprofen, naproxen, etc. for arthritis pain [26,27]. Certain clinical data 
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indicates an increased risk of cardiovascular complications in such patients, as compared to the 
patients taking aspirin alone [26,27]. The extensive studies of the interaction between aspirin and other 
NSAIDs in vitro and in clinic trials showed the ability of NSAIDs, such as celecoxib or naproxen, to 
suppress the aspirin-induced inhibitory effect on PGHS-1, their capabilities to prevent platelet 
aggregation, and blocking arteries [11,28]. 
To study the effect of NSAID interaction, we carried out in silico experiments with the 
combinations of aspirin and ibuprofen, as well as aspirin and celecoxib, in the different environmental 
conditions of PGHS-1. On the basis of the obtained results, we discuss the suppression mechanism of 
the aspirin-induced inhibitory effect on PGHS-1 by celecoxib and ibuprofen [11], and analyse the 
conditions which influence this effect. 
2. Kinetic Model of Inhibitory Action of NSAIDs on PGHS-1  
We have developed a kinetic model of the NSAID inhibition effect on PGHS-1, which includes 
detailed submodels of PGHS-1 catalysis and the enzyme interaction with NSAID [29]. Below we 
describe in brief our approach to modeling the complex functioning of PGHS-1 and the basic 
assumptions used on describing the action of different NSAIDs on PGHS-1.  
2.1. Detailed kinetic model of PGHS-1  
The developed scheme of the PGHS-1 catalytic cycle, including the interaction of the inhibitor with 
the enzyme, is shown in Figure 1. The bottom panel in Figure 1 shows the detailed catalytic cycle of 
PGHS-1 [29]. The upper panel presents the kinetic scheme of the interaction of inhibitor with  
PGHS-1. Below we describe in brief the kinetic model of PGHS-1 catalysis used in this work.  
The catalytic cycle proposed by us [29] is a further development of the approach based on the 
Branched Chain Mechanism of PGHS catalysis proposed by Dietz et al. [30] and elaborated further by 
Kulmacz et al. [31–34]. We considered the PGHS catalytic cycle as a system of elementary reactions 
between enzyme intermediates (Ei, i=1,…,23), arachidonic acid (AA), reducing cosubstrate (RC), 
intermediate, PGG2 and final, PGH2 products. The full catalytic cycle of PGHS was presented as a 
composition of eight interlinked cycles: five of them corresponding to peroxidase activity (POXi, 
i=1,…,5), the other three—to cyclooxygenase activity (COXi, i=1,2,3) of the enzyme. 
Two interconnected cycles, COX1 (reactions 1–4) and POX1 (reactions 9–13) correspond to the 
classical Branched Chain Mechanism of PGHS catalysis [30]. According to this mechanism, PGHS-1 
catalysis is initiated in the POX-site, and its first step is the reaction of the resting enzyme [Fe(III), PP] 
(E1) with PGG2, and production of PGH2  (reaction 11), followed by leaving the heme prosthetic group 
in the state [Fe(IV), PP*+] (E2, Intermediate I). The E2 state can be converted back to the resting state 
E1 by two consecutive reactions with an external reducing cosubstrate, RC, with a release of oxidised 
cosubstrate, OC (reactions 10 and 12). Alternatively, the E2 state can undergo a one-electron internal 
reduction via intramolecular electron transfer from the tyrosine 385 residue (Tyr385) to a 
protoporphyrin group (reaction 13), resulting in the formation of the E5 state, [Fe(IV), PP, Tyr*] 
containing the Tyr385* radical and a ferryl heme (Intermediate II). The E5 state can also complete the 
POX cycle and return to the resting state E1 via reactions 9 and 10 with cosubstrate. According to the 
Branched Chain Mechanism, the presence of the Tyr385* radical is ultimately required for the 
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activation of AA oxidation reaction in the COX-site [1,35]. Thus the intermediate state E5 potentially 
serves as a starting point for the further cascade of the cyclooxygenase catalysis. 
Figure 1. Scheme of catalytic cycle of PGHS with consideration of the enzyme inhibition 
by NSAID. Bottom panel—catalytic cycle of PGHS; top panel—scheme of NSAID (Inh) 
binding with the enzyme (thick lines); AA—arachidonic acid; RC—reducing cosubstrate; 
OC—oxidized RC; O2—oxygen; PGG2, PGH2—prostaglandin G2 and H2, respectively; 
Ei—enzyme states; Fe(III) and F(IV)—ferric and oxiferryl states of heme iron; PP and 
PP*+—protoporphyrin group in ground and radical cation states; Tyr, Tyr*—Tyrosine 385 
in ground and radical states; FIE—full inactivated enzyme state; cross—enzyme 
inactivated sites; dashed lines—reactions of self-inactivation of PGHS. 
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Reaction 1 describes a reversible binding of AA with the enzyme state E5, resulting in the 
formation of the state [Fe(IV), PP, Tyr*, AA] (E9), containing AA in the COX-site. Reaction 2 
corresponds to the abstraction of a hydrogen atom from AA by Tyr385* radical and formation of the 
E13 enzyme state containing AA* radical in the COX-site, [Fe(IV), PP, Tyr, AA*]. This AA* radical 
then reacts with two oxygen molecules and the intermediate product, PGG2* radical, is produced 
(reaction 3). The final step of the COX1 cycle in our model is the irreversible reaction 4, which 
describes the process of E5 state regeneration with Tyr385* radical, accompanied by the release of the 
intermediate product, PGG2 from the COX-site [1,2].  
Taking into account that POX activity of PGHS proceeds independently from COX catalysis [2,35], 
we considered in our model the possibility of several additional POXi and COXi catalytic cycles, 
originating from the intermediate states involved in POX1 and COX1 cycles. 
For example, the states of COX2 cycle originates from the states of COX1 cycle due to redox 
reactions with reducing cosubstrate, RC (reactions 19, 22, 28, and 29). 
Similarly, POX2, POX3, and POX4 cycles result from states E8, E9, and E13 respectively, which can 
participate in peroxidase reactions. These cycles differ from POX1 by the presence of AA, AA* and 
PGG*in the COX-site. 
The third COX3 cycle, though not explicitly shown in the scheme in Figure 1, can be defined as a 
cycle, formed by the enzyme states E7, E11, E19, and E21, involving reactions 47, 64, 33, and 53, 
respectively. Cycle POX5 was introduced to the model to account for the remaining POX activity of 
the enzyme, when COX-site is inactivated. 
In the model we have taken into account the process of irreversible self-inactivation of the enzyme 
during catalysis [36–38]. Self-inactivation is assumed to be caused by radical damage of the relevant 
catalytic domains of the enzyme, occurring when it is functioning [3]. As a result of self-inactivation, 
the enzyme works for approximately 20 seconds. In the model [29], we have considered  
self-inactivation of COX and POX activities separately, distinguishing between the inactivation, which 
originates from the enzyme intermediates with different redox states of heme group, and marked out 
the inactivation processes proceeding from the states with one or two radicals in the catalytic  
domains [38]. Inactivation stages are shown as the dashed arrows in the scheme in Figure 1.  
We took into account the heterodimer structure of PGHS [1,2] in the model by using double 
concentration of the enzyme in in silico experiments, in comparison with the enzyme concentration in 
the experimental assay. 
2.2. Consideration of NSAID Effects in the Model 
We extended our models [29] to account for inhibitory effects of various types of NSAIDs, among 
them: irreversible/reversible, time-dependent/time-independent, selective to PGHS-1 or PGHS-2 inhibitors.  
The upper panel in Figure 1 shows the scheme of the interaction between the competitive inhibitor 
and the enzyme. In our model we considered NSAID binding to the unoccupied COX-site (E1, E2, E3, 
E5, and E15 enzyme states), competing with arachidonic acid. Binding of a NSAID with the COX-site 
was modeled by mass action reaction and characterised by two kinetic parameters: the reaction rate, 
kon, and dissociation, Kd, constants. 
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In the model we assumed that NSAIDs mainly inhibit COX activity of PGHS-1 with no pronounced 
effect on its POX activity. In Figure 1 (upper panel) the POX6 cycle corresponds to the surviving POX 
activity of the enzyme bound with an inhibitor. The consideration of the surviving POX activity at the 
NSAID binding with PGHS in the model means that the enzyme bound with NSAID is incapable of 
catalysing COX reactions, but is still able to convert PGG2 to PGH2 in POX6 cycles. As it will be 
shown below, this effect manifests itself noticeably in PGHS-1 inhibition by NSAIDs. 
Note that the surviving POX activity of PGHS-1, inhibited by NSAID, has been established 
experimentally [39]. Although the presence of NSAID in the COX-site is likely to influence the 
functioning of the POX cycle, as a result, for example, of change in Tyr385* radical formation 
kinetics, caused by bound NSAIDs [40,41]. 
2.3. The Method of in silico Screening of NSAID Action on PGHS-1 
A kinetic model of the inhibition effect of NSAIDs on PGHS-1 was constructed in accordance with 
the developed catalytic cycle of PGHS-1 with consideration for the enzyme interaction with NSAID 
(see Figure 1) [29]. The model includes a system of 42 ordinary differential equations (ODEs), 
describing the dynamics of 26 enzyme catalytic states (Ei), six metabolites (AA, O2, RC, OC, PGG2, 
and PGH2) and inhibitor binding with the enzyme [29]. To run the computational simulation and to 
analyse the results, we used the following software packages for kinetic modeling: DBsolve 6.1 [42] 
and SimBiology (MATLAB, The MathWorks Inc.).  
This model was used for in silico screening of the inhibition actions of different NSAIDs on  
PGHS-1 in in vitro experimental conditions. To simulate the in silico experiments on the NSAID 
interaction with PGHS-1 under in vivo conditions (platelets, endothelial cells), we have upgraded our 
model in such a way that allows taking into account the synthesis and degradation of PGHS-1 in the 
cells (see Figure 1) [29].  
We also updated our model [29] to consider the reactions of PGHS-1 with external peroxide, ROOH. 
The reactions V99 = k7 ·ROOH·E1, V100 = k7· ROOH·E10, V101 = k7 ·ROOH·E12, V102 = k7 ·ROOH·E16,  
V103 = k7 ·ROOH·E18, and V104 = k7·ROOH·E24 were added to the catalytic cycle of PGHS-1 (see 
reaction V99 in Figure 1), as well to the system of ODEs. This allowed us to study the effect of external 
peroxide on PGHS-1 inhibition by NSAID. Note that in our simulation we used the kinetic properties 
of external peroxide as being the same as the peroxide PGG2’s properties. 
2.4. Mechanism of PGHS-1 regulation by arachidonic acid and reducing cosubstrate  
The main distinction between the in vitro and in vivo experiments on the measurement of the 
NSAID dose dependencies lies in the different concentrations of substrate and reducing cosubstrate in 
the experimental assays. In the in vitro experiments with the purified enzyme or a microsomal assay, 
high concentrations of arachidonic acid are commonly used, i.e., 30–100 µM [7,11–13], whereas in the 
in vivo experiments, the activation of platelets, endothelial cells, or blood assay is carried out by 
calcium ionophore or exogenous AA [9,13–17], and the intracellular concentration of free arachidonic 
acid is assumed to be less. In accordance with the estimates, the free AA concentration in platelets is in 
the range 0.001 µM–0.1 µM, depending on the platelet state [43,44].  
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Figure 2. Working region of PGHS-1 depending on concentrations of arachidonic acid, 
AA and reducing cosubstrate, RC (phenol). 
 
Also, the type and the concentration of the reducing substrate, RC, in in vitro experiments are 
known and fixed (phenol, tetramethyl-p-phenylenediamine, 50–500 µM), while in in vivo experiments 
with intact cells, the type of intracellular reducing cosubstrate and its level are unknown.  
The factors mentioned above may change the value of NSAID’s IC50, depending on the 
experimental settings. In particular, it is known from the enzymatic theory that the dependence of the 
competitive inhibitor IC50 on the substrate concentration, S, may be written as: 
50 1d
m
SIC K
K
 
= + 
 
 (1)  
where Km—Michaelis constant for the substrate, Kd—the dissociation constant of inhibitor. Equation 
(1) shows that less competition of inhibitor with substrate at low substrate concentration (AA) causes 
the NSAID IC50 to decrease. Thus, the increase of NSAID effect in in vivo conditions may be 
expected. It has been shown that relation (1) holds in the wide range of the substrate concentrations for 
PGHS-1 [29]. However, simple dependence of IC50 on AA concentration (1) is complicated by the 
complex kinetics of PGHS-1, particularly due to the existence of activation threshold in the range of 
low AA concentration [33].  
Furthermore, reducing cosubstrate exerts a complex influence on the enzyme activity. Cosubstrate 
has been established to be an activator at low concentration and a suppressor of PGHS-1 activity at 
high concentrations of cosubstrate [35].  
To study the dependence of PGHS-1 activity on AA and RC concentrations in detail, we carried out 
an in silico screening of oxygen consumption of PGHS-1 over a wide range of substrate and 
cosubstrate concentrations. Figure 2 shows the theoretical activation threshold curve, plotted on a 
plane of AA against RC concentrations. This curve divides the AA-RC plane into two areas: the 
enzyme is inactive in the AA and RC concentration range lying below the curve, and it is active in the 
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upper range. According to the obtained data, the activation threshold values of AA concentration 
lowers to 0.01 µM in the range of RC concentration less than 10 µM, and increases up to 1 µM at RC 
concentration of up to 5,000 µM. Note that the obtained activation region of AA concentrations is near 
the estimate of the free AA concentration in platelets (0.001 µM– 0.1 µM) [44]. Below we suggest that 
in cellular conditions, PGHS-1 functions close to its activation threshold level (0.01 µM–1 µM). 
The obtained results show that the activation threshold of PGHS-1 depends not only on the internal 
properties of the enzyme [45], but also on external conditions—the concentration of RC and AA. Other 
external factors affecting the activation threshold of PGHS-1,2 have been established to be peroxide, 
ROOH [33], and peroxidase levels [46]. Below we show that NSAID inhibition effect changes 
significantly near the activation threshold, which is determined by the AA, RC, and ROOH levels.  
3. In silico Screening of NSAID Effects at the Different Microenvironments of PGHS-1  
3.1. In silico experiment on aspirin action on PGHS-1 under in vitro/in vivo conditions 
Binding with PGHS-1, aspirin modifies the enzyme covalently by acetylation of the serine residue 
Ser-530 in the COX-site. This causes complete inhibition of the COX activity of PGHS-1 [1]. In our 
model, the irreversible PGHS-1 acetylation reaction (see reactions 69–73 in Figure 1) was modeled by 
action mass rate equation with a rate constant kon,aspirin =10−5 µM−1 s−1 [29], which was estimated based 
on literature data [11,15,16]. Note that in the model, it is assumed that acetylated PGHS-1 retains its 
POX activity and is able to reduce PGG2 to PGH2 (see POX6 cycle in Figure 1).  
In the in silico experiment on aspirin inhibition of PGHS-1, we reproduced the experimental 
conditions of the real experiment, carried out with purified PGHS-1 [11]. In that experiment, purified 
PGHS-1 (0.05 µM) was preincubated for 30 minutes with different concentrations of aspirin  
(0–200 µM), and then substrate, AA (100 µM) and cosubstrate, RC (100 µM) were added to initiate 
the PGHS-1 catalysis, followed by measurement of the oxidation rate of reducing cosubstrate. Note 
that these values of AA and RC concentrations, corresponding to in vitro experimental conditions, lay 
far from the activation threshold of PGHS-1, obtained by us (see Figure 2).  
According to the simulation of the dose dependence for aspirin shown in Figure 3 (red line) the 
value of the IC50 of aspirin equals 50 µM [11]. The experimentally obtained value of the aspirin IC50, 
measured in the different studies of purified PGHS-1 lays in the range of 30 µM–200 µM [13,14]. The 
in silico experiments, carried out at different experimental conditions, such as preincubation time, 
concentrations of AA and RC, showed that a variation of experimental settings leads to a change of the 
aspirin IC50 in the range mentioned above (results not shown). 
Extensive experimental studies of aspirin effect on intact cells (platelets, endothelial cells, 
fibroblast, and WBA) [11,13,14,17] showed that the aspirin IC50, measured in vivo experiments, is 
much lower (1–3 µM), than the IC50 obtained in in vitro assays. To analyse this discrepancy, we 
carried out the in silico experiments, simulating the experiments on aspirin effect on platelets. 
Generally in such experiments, platelets are treated with the different concentrations of aspirin during 
the preincubation period of 25–30 minutes, and then the production of TxA2 is stimulated by calcium 
ionophore. The resulting concentration of TxB2 is then measured in 10–15 minutes [11].  
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Figure 3. Dose dependence for aspirin calculated for purified PGHS-1 (red line) and 
platelet PGHS-1 (blue line). The enzyme activity (oxygen consumption (red line) and 
production of PGH2 (blue line)) is given in relative units. 
 
In the in silico experiment under in vivo conditions, we adjusted our method to the simulation of  
PGHS-1 catalysis in the platelet environment. The following assumptions were used in the calculation: 
(1) There is no de novo synthesis of PGHS-1 in platelets (ksyn = 0), but platelets contain a PGHS-1 
depot. We estimated this initial concentration of PGHS-1 equal to 2.5 µM [29], based on the 
experimentally measured amount of TxA2, produced after platelet stimulation [11]. (2) PGHS-1 
degradation rate, kdeg, was set as 10−5 s−1 based on the experimental estimation of PGHS half-life [47]. 
(3) Intracellular concentration of reducing cosubstrate was assumed to be in the range of 100 µM, and 
its biochemical properties close to the properties of phenol, used commonly in in vitro experiments, as 
a cosubstrate. 
The preincubation of platelets with aspirin and platelet activation by calcium ionophore were 
simulated by the following way: we assumed that in resting platelets, the concentration of AA is in the 
range of 0.01 µM–0.001 µM. As can be seen from Figure 2 this region lays below the activation 
threshold of PGHS-1 and corresponds to inactive PHGS-1. To simulate the effect of platelet 
stimulation by calcium ionophore, we increased AA concentration up to 0.1 µM. According to 
working diagram of PGHS-1 (see Figure 2), this leads to overcoming the activation threshold, and the 
start of PGH2 production. Thus we assumed that PGHS-1 functions in platelets at AA, RC 
concentrations close to its activation threshold (see Section 2.4 and Figure 2). Note that such a value 
range of AA concentrations is in accordance with the estimate of AA concentration in platelets, being 
in the range of 0.001 µM–0.1 µM, depending on the platelet state [44]. 
The resulting dose dependence curve for aspirin, acting on platelets, is presented in Figure 3  
(blue line). The aspirin IC50 in this case is approximately 2 µM, which is in agreement with numerous 
experimental data obtained in experiments with washed platelets [11], and human PGHS-1  
WBA [10,17]. 
As can be seen from the comparison of two theoretically derived dose dependencies shown in 
Figure 3, our model predicts a much stronger inhibitory effect of aspirin in vivo, as compared to 
in vitro conditions. This is indicated by a 100-fold smaller value of the aspirin IC50, obtained in in vivo 
experimental conditions (1 µM), as compared to the IC50 estimate, derived from the in vitro one  
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(100 µM). An analysis of the results obtained in in vitro and in vivo conditions allowed us to draw a 
conclusion on the possible mechanism, underpinning the stronger inhibitory effect of aspirin in vivo. 
Figure 4. Scheme of the kinetic interaction between acetylated and non-acetylated PGHS-1 
through common substrate, PGG2 at aspirin action. ROOH—external peroxide. 
 
The in silico experiment showed that this phenomenon originates from some complex enzyme 
dynamics, observed  in the AA-RC concentration range close to the activation threshold of PGHS-1. In 
this range the interaction between catalytic activities of acetylated and non-acetylated (intact) forms of 
the enzyme contributes significantly to the inhibition of PGHS-1 (see scheme in Figure 4). An 
accumulation of acetylated PGHS-1 within the cells occurs during preincubation of platelets with 
aspirin. As discussed in Section 2.2, the acetylated form of PGHS-1, while being inactive with regard 
to COX activity, can still catalyse peroxidase reaction. Residual POX activity of the acetylated enzyme 
leads to a fast depletion of the intermediate product, PGG2 from the system (see Figure 4). In this case 
acetylated PGHS-1 plays a role of scavenger of peroxide, PGG2 [46]. Lack of the intermediate product 
disturbs PGHS-1 autocatalysis and contributes to the resulting inhibition of COX activity of the 
enzyme. Thus, the direct inhibitory effect of aspirin (due to acetylation of PGHS-1) is enhanced by its 
indirect action, resulting from scavenging intermediate product, PGG2 by the acetylated enzyme. Note 
that a kinetic interaction of acetylated and non-acetylated PGHS-1 results in a more pronounced effect 
on the enzyme inhibition at the concentrations of AA and RC close to the activation threshold (in vivo 
conditions), rather than far from one (in vitro conditions). 
3.2. Effects of peroxide and reducing cosubstrate on PGHS-1 inhibition by aspirin  
3.2.1. The suppression effect of external peroxide on aspirin-mediated inhibition of PGHS-1  
According to the observed effect of the interaction between acetylated and non-acetylated PGHS-1, 
discussed in Section 3.1, the decrease in peroxide PGG2 levels due to the residual POX activity of 
acetylated PGHS-1, leads to a rise in aspirin efficacy. Based on this observation, we suggested that the 
addition of peroxide to the assay may cause the opposite effect—weakening of aspirin inhibition 
action. To test this assumption, we updated our model to take into account the reaction of PGHS-1 
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with peroxide, ROOH (see Section 2.3. and Figures 1, 4) and carried out in silico experiment on 
aspirin action on platelet PGHS-1 in the presence of external peroxide, ROOH. 
The dose dependence of platelet PGHS-1 inhibition by aspirin, simulated in the presence of 
additional peroxide, is shown in Figure 5(a). As seen from the comparison of two dose dependencies, 
calculated in the absence/presence of external peroxide [blue and red lines, respectively, in  
Figure 5(a)], the addition of peroxide causes the shift of the dose dependence to the higher 
concentration of aspirin (red line), and increase of the aspirin IC50 from 2 µM to 50 µM. This result 
shows that external peroxide decreases the efficacy of aspirin inhibition of PGHS-1.  
Figure 5. (a) The dose dependencies for aspirin calculated for PGHS-1 at the absence (blue 
line) and presence (red line) of external peroxide, ROOH; (b) The dose-dependences for 
aspirin calculated at the different cosubstrate (phenol) concentrations: 300 µM (blue line) 
and 100 µM (red line). PGHS-1 activity (oxygen consumption) is given in relative units. 
 
In our approach this effect is explained by a weakening of the kinetic interaction between acetylated 
and active PGHS-1 upon the addition of external peroxide. The consumption of peroxide, PGG2 by 
acetylated PGHS-1 decreases partially due to the presence of external peroxide. It leads to acetylated 
PGHS-1 interfering less with active PGHS-1. Thus, external peroxide abrogates the additional 
inhibition effect, brought about by the interaction of acetylated and active PGHS-1 through the 
common metabolite, peroxide PGG2.  
Note that the effect of suppression of aspirin action, observed in in silico experiments, has been 
observed in in vitro experiments [6], in which external peroxide (12-HPETE) was obtained to decrease 
the aspirin-mediated inhibition of purified PGHS-1. It is also to be noted that the experimental 
conditions, used in the experiments [6], are close to the initial conditions in the in silico experiment, 
namely: the concentrations of ovine PGHS-1 = 1.5 µM, AA = 0.5 µM, and preincubation time equal to 
30 minutes. 
Moreover, experiments with cellular culture treated by aspirin have shown that the efficacy of 
aspirin is more than 20 times higher in A549 cells possessing a low level of hydrophobic 
hydroperoxides, than in RAW 264.7 cells, in which hydroperoxides are produced in quantity [6].  
The authors of [6] proposed the hypothesis that the suppression mechanism of the aspirin-mediated 
inhibition of PGHS-1 by peroxide is determined by the effect of enzyme POX activity on Ser530 
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acetylation by aspirin. The Tyr385 residue was assumed to participate in aspirin binding with Ser530. 
Oxidation of Tyr385 and formation of a Tyr385 radical due to peroxide activate the POX reaction, 
suppressing the aspirin binding with Ser530, and thus inhibiting PGHS-1 acetylation.  
In our approach, the POX activity of the enzyme plays a key role in the suppression effect of the 
aspirin-mediated inhibition of PGHS-1 by external peroxide as well. But the in silico experiment 
showed that the POX activity of acetylated PGHS-1 in the presence of external peroxide affects the 
inhibition of active PGHS-1 less, than in the case of the absence of external peroxide (see discussion in 
Section 3.1). Thus, the addition of external peroxide leads to the decrease in suppression action of the 
POX activity of acetylated PGHS-1 on the non-acetylated enzyme.  
The obtained results lead one to conclude that different peroxide status of different cells, as well as 
a change in peroxide level of cells, as a result of diseases, may alter the aspirin efficacy and cause 
aspirin resistance [28]. 
3.2.2. Effect of reducing cosubstrate on the aspirin-mediated inhibition of PGHS-1 
In Section 2.4 we showed that the reducing cosubstrate substantially influences the activation 
threshold of PGHS-1 (see working diagram in Figure 2). The activity of the enzyme drops dramatically 
near the threshold region of cosubstrate concentrations. Note that the threshold RC concentration for 
PGHS-1 has been established experimentally [35]. As we suggested, PGHS-1 functions in a cell at the 
cosubstrate concentrations near its activation threshold (see Figure 2). Further we study the effect of 
RC on inhibition effect of aspirin in the RC concentration range near the activation threshold.  
Figure 6. The dependence of the aspirin IC50 on cosubstrate (phenol) concentration, RC 
calculated for purified PGHS-1. 
 
Figure 5(b) shows the theoretical dose dependencies for aspirin calculated at RC concentrations, 
300 µM and 100 µM (blue and red lines, respectively). As it can be seen from the working diagram in 
Figure 2, the first simulation was carried out at the concentration value closer to the activation 
threshold (AA = 0.1 µM, RC = 300 µM) than the second one (AA = 0.1 µM, RC = 100 µM). The 
comparison of two dose dependencies, given in Figure 5(b) shows that moving of AA,RC-region far 
from the activation threshold leads to the shift in the dose dependence to the higher concentrations of 
aspirin, and an increase in its IC50 from 2 µM up to 40 µM. These results of the in silico screening of 
the aspirin IC50 show that the efficacy of aspirin falls off with RC concentration (see Figure 6). It is to 
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be mentioned that the most pronounced effect of RC on the aspirin IC50 is observed in the RC 
concentration region, close to the activation threshold of PGHS-1. 
3.3. In silico screening of reversible inhibitor actions in different environmental conditions of PGHS-1 
We applied the developed method to in silico experiments with reversible PGHS-1 inhibitors, such 
as celecoxib and ibuprofen. Celecoxib is a reversible, time-independent, selective inhibitor of PGHS-2, 
with selectivity equal to 0.1–0.7 (ratio of IC50 of PGHS-2 to IC50 of PGHS-1) [7,9,18], and ibuprofen is 
a reversible, time-independent, selective inhibitor of PGHS-1 with a selectivity of 0.67–53.3 [10].  
To estimate the affinities of these drugs to PGHS-1, we reproduced in silico the in vitro experiments 
on the inhibitory actions of celecoxib and ibuprofen on purified PGHS-1 [7], and obtained their kinetic 
parameters as a result of the fitting of the experimental and simulation dose dependencies for celecoxib 
and ibuprofen. We obtained the following values of the reaction rate and dissociation constants of 
celecoxib: kon,celecox = 1.6 µM−1 s−1, Kd,celecox = 0.2 µM and ibuprofen: kon,ibuprofen = 7 µM−1 s−1,  
Kd,ibuprofen = 0.1 µM. Both the theoretical and experimental [7] dose dependence curves for celecoxib 
and ibuprofen are presented in Figure 7. The calculated IC50 of celecoxib and ibuprofen are in the 
range of 30 µM. The experimental values of the IC50 of ibuprofen lay in the wide range of the 
concentrations, 3.3 µM–100 µM [7,13,48–50].  
We applied our technique to translate the results obtained in the in vitro conditions to the in vivo 
ones. The in silico screening of the drug action on platelet PGHS-1 was carried out at the 
concentrations of RC and AA near the activation threshold of the enzyme (see Figure 2). The details of 
the experimental procedure and computer simulation are the same as in the case of the in silico study 
of aspirin action on platelets, described in Section 3.1.  
Figure 7. The dose dependencies of PGHS-1 inhibition by celecoxib (a) and ibuprofen (b) 
calculated for purified (red line) and platelet PGHS-1 (blue line). Points—experimental 
data for purified PGHS-1 [7]. The enzyme activity (oxygen consumption (a) and 
production of PGH2 (b)) is given in relative units. 
 
The calculated dose dependencies for celecoxib and ibuprofen are shown in Figure 7. Similarly to 
the aspirin case (see Section 3.1), celecoxib and ibuprofen demonstrate substantially more potent 
effects in in silico experiment with the in vivo experimental conditions than in in vitro settings. We 
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established two key mechanisms of the changes in celecoxib and ibuprofen inhibitory effect in in vivo 
conditions. The first one is due to the additional suppression effect, caused by the interference between 
the residual POX activity of PGHS-1 bound with inhibitor and active PGHS-1. This mechanism, 
discussed in Section 3.2, manifests itself near the activation threshold of the enzyme, and causes the 
shift and shape change of the dose dependence. 
The second reason for the decrease in IC50 is the concentration of the substrate, AA, being lower in 
in vivo experiments compared to in in vitro ones. As celecoxib and ibuprofen are fast, reversible 
inhibitors of PGHS-1, competing with the substrate, the dependencies of their IC50s on the substrate 
concentration may be approximately described by equation (1). According to this dependence, the fall 
in the AA concentration leads to the decrease in the IC50 value. Note that this mechanism, caused by 
the drug and AA competition, does not show up in the case of in vitro and in vivo experiments with 
platelets treated by slow irreversible inhibitor, aspirin. This effect is due to the fact that enzyme binds 
with aspirin in the absence of competitive substrate at the preincubation stage. 
The obtained value of the celecoxib IC50 (1 µM) is in agreement with the experimental values 
[9,11,18], which vary in the range from 1.2 µM to 10 µM [9,11,18]. The observed differences in the 
reported values of the celecoxib IC50 are most likely to be explained by the variations in the 
experimental conditions used in different studies. For example, some experiments were performed on 
washed platelets [11], whereas the others—on human PGHS-1 WBA [9]. The methods of platelet 
activation were different as well: stimulation by exogenous AA, or calcium ionophore. Note that 
platelet activation methods have been reported to influence significantly the IC50 value [50]. 
The results of our calculations also showed that ibuprofen produces a stronger inhibitory effect on 
PGHS-1 in vivo condition than in vitro one. The obtained value of the ibuprofen IC50 is 2 µM, which is 
in agreement with the experimental data, measured in the different experimental conditions: 7.6 µM 
(WBA) [9], 1.4 µM–0.4 µM (washed platelets) [11], 5 µM (bovine aortic endothelial cells) [13].  
The in silico screening of celecoxib and ibuprofen actions on PGHS-1 showed that these two drugs 
with different selectivity to PGHS-1 possess approximately equal abilities to inhibit PGHS-1 in 
platelets and in in vitro conditions. Below we continue to compare these NSAIDs by using in silico 
experiments in the different experimental conditions. 
3.4. In silico screening of combined effects of NSAIDs on PGHS-1 inhibition in vitro/in vivo conditions  
The problem of NSAID co-administration is being actively discussed in literature in the context of 
uncertainty of the resulting therapeutic and side effects which arise from such combinations 
[11,26,27]. Both in vitro and in vivo experiments, as well as clinical studies, demonstrate that some 
nonselective NSAIDs (ibuprofen, naproxen) [11,26] and PGHS-2 selective NSAIDs (celecoxib, 
valdecoxib, etoricoxib) [11] can undermine the aspirin-mediated inhibition of purified and cellular 
PGHS-1. That suppression effect is assumed to be caused by the interference of aspirin and some 
NSAIDs upon their competitive binding with PGHS-1 [28]. But, the detailed mechanism of such 
suppression has been difficult to explain satisfactorily.  
To elucidate the mechanism of the interference of NSAIDs, we adapted our method to the in silico 
screening of the resulting effect of two NSAIDs in combination on PGHS-1 in vivo and in vitro 
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conditions. In this section, we demonstrate the application of our method to in silico study of the 
combined effects of aspirin and ibuprofen, as well as aspirin and celecoxib.  
In in silico experiments we reproduced the conditions of the experiments on a combined action of 
aspirin with celecoxib, and aspirin with ibuprofen on PGHS-1 in vitro conditions and platelets [11]. In 
the experimental study, purified PGHS-1 was preincubated with 200 µM aspirin and different 
concentrations of ibuprofen (celecoxib) for 30 minutes [11]. Cyclooxygenase reaction was then 
initiated by the addition of 100 µM of arachidonic acid and 100 µM of reducing cosubstrate 
(tetramethyl-p-phenylenediamine), and the rate of cosubstrate oxidation was monitored 
spectrophotometrically [11]. The experimentally measured dose dependencies for ibuprofen 
(celecoxib) are presented in Figure 8 (points). In the in silico experiment we used kinetic parameters of 
aspirin, ibuprofen, and celecoxib identified previously (see Section 3.3).  
Figure 8. Effect of the suppression of aspirin-mediated inhibition of purified PGHS-1 by 
ibuprofen and celecoxib. The dose dependence of PGHS-1 inhibition by ibuprofen (a) and 
celecoxib (b) at the presence of 200 µM aspirin. Lines—theoretical results, points—
experimental data [8]. Inhibition of oxygen consumption by PGHS-1 is given in  
relative units.  
 
The obtained theoretical dose dependencies for ibuprofen and celecoxib in the presence of 200 µM 
aspirin are shown in Figure 8 (solid lines). As it can be seen, the calculated curves provide a good 
agreement with the experimental data [11], shown by points in Figure 8. The resulting dose 
dependencies demonstrated that ibuprofen and celecoxib suppress the inhibitory effect of aspirin by 
80% and 90%, respectively, in the drug concentration range of 0.2 µM–100 µM. The minimum of 
inhibition is reached at approximately 4 µM for ibuprofen and 10 µM for celecoxib. The increase of 
drug concentrations leads to a full recovery of the inhibitory effect of the drug combination. 
In the framework of our model, the observed suppression effect of the aspirin-mediated inhibition 
of PGHS-1 by ibuprofen or celecoxib may be explained by the complex kinetic interplay of three 
species—aspirin, ibuprofen (celecoxib) and arachidonic acid—all competing for the same COX 
binding site of the enzyme. These three small molecules differ by their kinetic properties—the rate of 
binding and the affinity to the COX-site of the enzyme, which results in an antagonistic effect between 
these species in the wide range of their concentrations. As has been established experimentally [8] and 
Pharmaceuticals 2010, 3                  
          
 
2075 
theoretically, 200 µM of aspirin is enough to completely acetylate 0.5 µM of PGHS-1 in the end of 30 
minutes preincubation period [see the initial point on the dose dependence curve at zero concentration 
of ibuprofen (celecoxib) in Figure 8]. Addition of ibuprofen (celecoxib) at the preincubation stage 
results in the competitive binding of two inhibitors with PGHS-1 which leads to the formation of two 
enzyme states: acetylated PGHS-1 and PGHS-1 bound with ibuprofen (celecoxib). The relation among 
the concentrations of these enzyme states and the free enzyme is defined by the preincubation time and 
the kinetic properties of the drugs. In general, ibuprofen (celecoxib) binds with PGHS-1  
(kon,ibuprofen = 7 µM−1 s−1; kon,celecox = 1.6 µM−1 s−1) faster than aspirin (kon,aspirin = 10−5 µM−1s−1), and 
therefore tends to replace aspirin molecule in the COX-site at the high concentration of ibuprofen 
(celecoxib). It leads to saving some part of PGHS-1 from irreversible acetylation by aspirin. The 
substitution of aspirin by ibuprofen (celecoxib) starts when the drug concentration is in the range of the 
dissociation constants of ibuprofen, Kd,ibuprofen = 0.1 µM or celecoxib, Kd,celecox = 0.2 µM  
(see Section 3.2). The simulation of the preincubation stage showed that at 10 µM of celecoxib, 90% 
of PGHS-1 are bound with celecoxib, while the rest 10% are bound with aspirin. Note that in the end 
of the preincubation period (30 minutes), all PGHS-1 are totally inhibited by aspirin and ibuprofen 
(celecoxib). When the enzyme substrate AA is added, it gets involved in the antagonistic interplay with 
ibuprofen (celecoxib) for the COX-site. As our calculations have shown, the dissociation constant of 
ibuprofen (celecoxib) is close to the one of AA (Kd,AA = 0.1 µM [29]). Considering this and the fact 
that the concentration of AA in the experiment equals to 100 µM [11], AA intensively replaces 
ibuprofen (celecoxib) in the COX-site of the enzyme, and activates it at low ibuprofen (celecoxib) 
concentrations (0.1 µM–1 µM). It results in the inhibition dose dependence falling in the range of 
ibuprofen (celecoxib) concentrations 0.1 µM–1 µM (see Figure 8). 
The rise in the inhibition dose dependence curve observed in the range of 10 µM–100 µM of 
ibuprofen (celecoxib) concentrations is determined by the inhibition action of ibuprofen (celecoxib) in 
the region of its IC50 (≅30 µM).  
The suppression effect of ibuprofen (celecoxib) on the aspirin-mediated inhibition of PGHS-1 has 
been confirmed in experiments on platelets [11] (see experimental data in Figure 9). To analyse the 
difference in these effects in the cases of in vitro and in vivo experimental conditions, we carried out a 
computational simulation of the combined action of aspirin and ibuprofen (celecoxib) using the 
experimental conditions of the work [11]. In this experiment, platelets were treated with 0–100 µM 
ibuprofen (celecoxib) for five minutes before the addition of 100 µM aspirin. After 20 minutes 
incubation, the platelets were washed to remove the reversible inhibitor, and then activated by calcium 
ionophore. The amount of TXB2 produced was measured after 10 min of the cyclooxygenase reaction. 
In the in silico experiment the intracellular concentration of AA and RC were chosen near the 
activation threshold of PGHS-1 (see discussion in Section 3.1 and Figure 2). 
The theoretical dose dependencies for ibuprofen and celecoxib in the presence of 100 µM aspirin 
are shown in Figure 9 along with the experimental data [11]. These results show that the blocking 
effect of ibuprofen (celecoxib) on the aspirin-mediated inhibition of PGHS-1, observed on the purified 
enzyme, is maintained in in vivo case as well. However, there is the noticeable difference between 
these two cases. There is no restoration of the initial inhibition level in the range of ibuprofen 
(celecoxib) concentrations higher than 10 µM. The activation of platelets at these drug concentrations 
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is determined by complete removal of ibuprofen (celecoxib) from intercellular environment  
of platelets [11].  
Figure 9. Effect of the suppression of aspirin-mediated inhibition of platelet PGHS-1 by 
ibuprofen and celecoxib. The dependence of platelet PGHS-1 inhibition on ibuprofen (a) 
and celecoxib (b) concentrations at the presence of 100 µM aspirin at the full removal of 
ibuprofen (celecoxib) after preincubation. Lines—theoretical results on the inhibition of 
PGH2 production, points—experimental data on the inhibition of TXB2 production [8]. 
 
To estimate the impact of intercellular concentration of the drug on the blocking effect, we repeated 
the in silico experiment under the conditions of partial removal of celecoxib after the preincubation 
stage. The resulting dose dependence, given in Figure 10, showed the disappearance of the dip on the 
dose dependence curve in the range of 1 µM celecoxib concentration when the residual concentration 
of celecoxib is rising. In contrast to in vitro case (see Figure 8), the blocking effect vanishes at the high 
concentrations of celecoxib in platelets (see line 7 in Figure 10). The dip disappearance on the dose 
dependence curve calculated for in vivo conditions is determined by the difference in the celecoxib 
IC50 obtained in in vitro and in vivo cases. As we have established above, a rise in the dose dependence 
at high drug concentrations is governed by the value of the celecoxib IC50.  
Under in vivo conditions, the celecoxib IC50 (1 µM) is less than in in vitro case (30 µM) and close to 
the minimum of the dose dependence curve (at 1 µM). In this case the dip in the dose dependence 
curve is not formed. Note that the same effect of the disappearance of the blocking effect was observed 
in the case of the combination of aspirin and ibuprofen (data not shown). Thus, the in silico 
experiments showed that blocking effects of ibuprofen and celecoxib on the aspirin-mediated 
inhibition of platelet PGHS-1 depend significantly on the drug concentration in the intercellular 
environment. So the further in silico study of the conditions, at which NSAIDs block aspirin inhibitory 
effect on PGHS-1 in platelets, needs the consideration of pharmacokinetic data. 
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Figure 10. Effect of the suppression of aspirin-mediated inhibition of platelet PGHS-1 by 
celecoxib. The theoretical dependencies of platelet PGHS-1 inhibition on celecoxib 
concentration calculated at the partial removal of celecoxib after preincubation.  
Line 1—100% removal of celecoxib, line 2—70%, line 3—50%, line 4—30%,  
line 5—20%, line 6—10%, line 7—no removal of celecoxib. Lines—theoretical results on 
inhibition of PGH2 production, points—experimental data on inhibition of TXB2 
production by platelets washed after preincubation [8]. Inhibition is given in relative units. 
Aspirin concentration—100 µM. 
 
4. Conclusions  
The developed method of the in silico experiments on NSAID action on PGHS-1 was shown to be a 
promising tool to be applied to the following problems of in silico pharmacology: 
• In silico screening of inhibition effects of different types of NSAIDs on PGHS-1 in various 
environmental conditions of the enzyme; 
• Dissection of the key factors, which determine the variability of PGHS-1 response to NSAID 
action in in vitro assays, platelets, endothelia and other cells; 
• In silico comparison of the different NSAIDs and the establishment of bioequivalence of the 
various drugs in the different experimental conditions; 
• Translation of the results on NSAIDs action on PGHS-1, obtained in in vitro experimental 
conditions to in vivo settings; 
• In silico study of the drug interference, underlying the combined action of two NSAIDs on 
PGHS-1 to predict the potential risks and benefits of NSAID combination therapy. 
The proposed method of the in silico screening of PGHS-1 inhibition by NSAIDs in the 
intracellular environments corresponding to the inflammation progression in different cells may be a 
useful technique for predicting the anti-inflammatory and adverse effects of NSAIDs and their 
combinations in the changeable intracellular conditions.  
 
Pharmaceuticals 2010, 3                  
          
 
2078 
Acknowledgements 
The authors wish to thank the financial input received from the UK Charity, Biosystems Informatics 
Institute of Newcastle-upon-Tyne without which this work would not have been possible. The Centre 
for Systems Biology at Edinburgh is a Centre for Integrative Systems Biology (CISB) funded by 
BBSRC and EPSRC, reference BB/D019621/1. 
References  
1. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: structural, cellular, and molecular 
biology. Annu. Rev. Biochem. 2000, 69, 145–182.  
2. Kulmacz, R.J.; van der Donk, W.A.; Tsai, A.L. Comparison of the properties of prostaglandin H 
synthase-1 and -2. Prog. Lipid Res. 2003, 42, 377–404.  
3. Tsai, A.L.; Kulmacz, R.J. Prostaglandin H synthase: Resolved and unresolved mechanistic issues. 
Arch. Biochem. Biophys. 2010, 493, 103–124. 
4. Kulmacz, R.J. Cellular regulation of prostaglandin H synthase catalysis. FEBS Lett. 1998, 430, 
154–157.  
5. Rouzer, C.A.; Marnett, L.J. Cyclooxygenases: Structural and functional insights. J. Lipid Res. 
2009, 50, S29–S34. 
6. Bala, M.; Chin, C.N.; Logan, A.T.; Amin, T.; Marnett, L.J.; Boutaud, O.; Oates, J.A. Acetylation 
of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem. 
Pharmacol. 2008, 75, 1472–1481.  
7. Gierse, J.K.; Koboldt; C.M.; Walker, M.C.; Seibert, K.; Isakson, P.C. Kinetic basis for selective 
inhibition of cyclo-oxygenases. Biochem. J. 1999, 339, 607–614.  
8. Ouellet, M.; Percival, M.D. Effect of inhibitor time-dependency on selectivity towards 
cyclooxygenase isoforms. Biochem. J. 1995, 306, 247–251. 
9. Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J. A.; Vane, J. R.. Nonsteroid drug 
selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human 
gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 1999, 96, 7563–7568.  
10. Brooks, P.; Emery, P.; Evans, J.F.; Fenner, H.; Hawkey, C.J.; Patrono, C.; Smolen, J.; Breedveld 
F.; Day, R.; Dougados, M.; Ehrich, E.W.; Gijon-Baños, J.; Kvien, T.K.; Van Rijswijk, M.H.; 
Warner, T.; Zeidler, H. Interpreting the clinical significance of the differential inhibition of 
cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999, 38, 779–788. 
11. Ouellet, M.; Riendeau, D.; Percival, M.D. A high level of cyclooxygenase-2 inhibitor selectivity 
is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. 
Proc. Nat. Acad. Sci. USA 2001, 98, 14583–14588. 
12. Callan, O.H.; So, O.-Y.; Swinney, D.C. The kinetic factors that determine the affinity and 
selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by 
indomethacin and flurbiprofen. J. Biol. Chem. 1996, 271, 3548–3554. 
13. Mitchell, J.A.; Akarasereenont, P.; Thiemermann, C.; Flower, R.J.; Vane, J.R. Selectivity of 
nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. 
Proc. Natl. Acad. Sci. USA 1994, 90, 11693–11697. 
Pharmaceuticals 2010, 3                  
          
 
2079 
14. Kargman, A.; Wong, E.; Greig, G.M.; Falgueyret, J.P.; Cromlish, W.; Ethier, D.; Yergey, J.A.; 
Riendeau, D.; Evans, J.F.; Kennedy, B.; Tagari, P.; Francis, D.A.; O'Neill, G.P. Mechanism of 
selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem. 
Pharmacol. 1996, 52, 1113–1125. 
15. Burch, J.W.; Baenziger, N.L.; Stanford, N.; Majerus, P.W. Sensitivity of fatty acid 
cyclooxygenase from human aorta to acetylation by aspirin. Proc. Natl. Acad. Sci. USA 1978, 75, 
5181–5184. 
16. Rome, L.H.; Lands, W.E.M. Structural requirements for time-dependent inhibition of 
prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Nat. Acad. Sci. USA 1975, 72, 
4863–4865. 
17. Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J.A.; Vane, J.R. Stronger 
inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than 
platelets offers an explanation for increased risk of thrombotic events. FASEB J. 2006, 20,  
2468–2475. 
18. Grosser, T.; Fries, A.; FitzGerald, G.A. Biological basis for the cardiovascular consequences of 
COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 2006, 116, 4–15. 
19. Sciulli, M.G.; Renda, G.; Capone, M.L.; Tacconelli, S.; Ricciotti, E.; Manarini, S.; Evangelista, 
V.; Rebuzzi, A.; Patrignani, P. Heterogeneity in the suppression of platelet cyclooxygenase-1 
activity by aspirin in coronary heart disease. Clin. Pharmacol. Ther. 2006, 80, 115–125 
20. Ben-Dor, I.; Kleiman, N.S.; Lev, E. Assessment, mechanisms, and clinical implication of 
variability in platelet response to aspirin and clopidogrel therapy. Am. J. Cardiol. 2009, 104,  
227–233. 
21. Folts, J.D.; Schafer, A.I.; Loscalzo, J.; Willerson, J.T.; Muller, J.E. A perspective on the potential 
problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model 
with clinical trials. J. Am. Coll. Cardiol. 1999, 33, 295–303.  
22. Steinhubl, S.R.; Charnigo, R.; Moliterno, D.J. Resistance to antiplatelet resistance is it justified? 
J. Am. Coll. Cardiol. 2005, 45, 1757–1758. 
23. Steinhubl, S.R. The use of anti-inflammatory analgesics in the patient with cardiovascular disease: 
What a pain. J. Am. Coll. Cardiol. 2005, 45, 1302–1303.  
24. Blobaum, A.L.; Marnett, L.J. Structural and functional basis of cyclooxygenase inhibition. J. 
Med. Chem. 2007, 50, 1425–1441.  
25. Huntjens, D.R.; Danhof, M.; Della Pasqua, O.E. Pharmacokinetic-pharmacodynamic correlations 
and biomarkers in the development of COX-2 inhibitors. Rheumatology 2005, 44, 846–859. 
26. Capone, M.L.; Sciulli, M.G.; Tacconelli, S.; Grana, M.; Ricciotti, E.; Renda, G.; Di Gregorio, P.; 
Merciaro, G.; Patrignani, P. Pharmacodynamic interaction of naproxen with low-dose aspirin in 
healthy subjects. J. Am. Coll. Cardiol. 2005, 45, 1295–1301. 
27. Curtis, J.P.; Krumholz, H.M. The case for an adverse interaction between aspirin and non-
steroidal anti-inflammatory drugs: Is it time to believe the hype? J. Am. Coll. Cardiol. 2004, 43, 
991–993.  
28. Patrono, C.; García Rodríguez, L.A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the 
prevention of atherothrombosis. N. Engl. J. Med. 2005, 353, 2373–2383. 
Pharmaceuticals 2010, 3                  
          
 
2080 
29. Goltsov, A.; Maryashkin, A.; Swat, M.; Kosinsky, Y.; Humphery-Smith, I.; Demin, O.; Goryanin, 
I.; Lebedeva, G. Kinetic modelling of NSAID action on COX-1: Focus on in vitro/in vivo aspects 
and drug combinations. Eur. J. Pharm. Sci. 2009, 36, 122–136. 
30. Dietz, R.; Nastainczyk, W.; Ruf, H.H. Higher oxidation states of prostaglandin H synthase. Rapid 
electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with 
prostaglandin G2. Eur. J. Biochem. 1988, 171, 321–328. 
31. Wei, C.; Kulmacz, R.J.; Tsai, A.L. Comparison of branched-chain and tightly coupled reaction 
mechanisms for prostaglandin H synthase. Biochem. 1995, 34, 8499–8512. 
32. Lu, G.; Tsai, A.L.; Van Wart, H.E.; Kulmacz, R.J. Comparison of the peroxidase reaction kinetics 
of prostaglandin H synthase-1 and -2. J. Biol. Chem. 1999, 74, 16162–16177. 
33. Wei, C.; Timothy R. Pawelek; Kulmacz R.J. Hydroperoxide dependence and cooperative 
cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J. Biol. Chem. 1999, 274,  
20301–20306.  
34. Bambai, B.; Rogge, C.E.; Stec, B.; Kulmacz, R.J. Role of Asn-382 and Thr-383 in activation and 
inactivation of human prostaglandin H synthase cyclooxygenase catalysis. J. Biol. Chem. 2004, 
279, 4084–4092.  
35. Bambai, B.; Kulmacz, R.J. Prostaglandin H synthase. Effects of peroxidase cosubstrates on 
cyclooxygenase velocity. J. Biol. Chem. 2000, 275, 27608–27614. 
36. Wu, G.; Kulmacz, R.J.; Tsai, A.L. Cyclooxygenase inactivation kinetics during reaction of 
prostaglandin H synthase-1 with peroxide. Biochem. 2003, 42, 13772–13777. 
37. Wu, G.; Wei, C.; Kulmacz, R.J.; Osawa, Y.; Tsai, A.L. A mechanistic study of self-inactivation of 
the peroxidase activity in prostaglandin H synthase-1. J. Biol. Chem. 1999, 274, 9231–9237.  
38. Song, I.; Ball, T.M.; Smith, W.L. Different suicide inactivation processes for the peroxidase and 
cyclooxygenase activities of prostaglandin endoperoxide H synthase-1. Biochem. Biophys. Res. 
Commun. 2001, 289, 869–875. 
39. Kulmacz, R.J. Topography of prostaglandin H synthase. J. Biol. Chem. 1989, 264, 14136–14144. 
40. Kulmacz, R.J.; Palmer, G.; Tsai, A.L. Prostaglandin H synthase: Perturbation of the tyrosyl 
radical as a probe of anticyclooxygenase agents. Mol. Pharmacol. 1991, 40, 833–837. 
41. Lassmann, G.; Odenwaller, R.; Curtis, J.F.; DeGray, J.A.; Mason, R.P.; Marnett, L.J.; Eling, T.E. 
Electron spin resonance investigation of tyrosyl radicals of prostaglandin H synthase. Relation to 
enzyme catalysis. J. Biol. Chem. 1991, 266, 20045–20055. 
42. Goryanin, I.; Hodgman, T.C.; Selkov, E. Mathematical simulation and analysis of cellular 
metabolism and regulation. Bioinformatics 1999, 15, 749–758. 
43. Brash, A.R. Arachidonic acid as a bioactive molecule. J. Clin. Invest. 2001, 107, 1339–1345.  
44. Sergeeva, M.G.; Varfolomeeva, A.T. Cascade of Arachidonic Acid; Public Education, Moscow, 
Russian, 2006. 
45. Hazelton, W.D.; Tien, J.H.; Donato, V.W.; Sparks, R.; Ulrich, C.M. Prostaglandin H synthases: 
Members of a class of quasi-linear threshold switches. Biochem. Pharmacol. 2004, 68, 423–432. 
46. Kulmacz, R.J.; Pendleton, R.B.; Lands, W.E. Interaction between peroxidase and cyclooxygenase 
activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics. J. Biol. 
Chem. 1994, 269, 5527–5536. 
Pharmaceuticals 2010, 3                  
          
 
2081 
47. Mbonye, U.R.; Wada, M.; Rieke, C.J.; Tang, H.Y.; Dewitt, D.L.; Smith, W.L. The 19-amino acid 
cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-
associated degradation system. J. Biol. Chem. 2006, 281, 35770–35778. 
48. Mancini, J.A.; Riendea, D.; Falgueyret, J.P.; Vickers, P.J.; O'Neill, G.P. Arginine 120 of 
prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory 
drugs containing a carboxylic acid moiety. J. Biol. Chem. 1995, 270, 29372–29377.  
49. Gierse, J.K.; Hauser, S.D.; Creely, D.P.; Koboldt, C.; Rangwala, S.H.; Isakson, P.C.; Seibert, K. 
Expression and selective inhibition of the constitutive and inducible forms of human cyclo-
oxygenase. Biochem. J. 1995, 305, 479–484. 
50. Chulada, P.C.; Langenbach, R. Differential inhibition of murine prostaglandin synthase-1 and -2 
by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic 
acid. J. Pharmacol. Exp. Ther. 1997, 280, 606–613. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
